Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:MGRX 13 November 2025 - 23 February 2026

Mangoceuticals stock slips before the bell after a 49% surge — what traders watch next for MGRX

Mangoceuticals stock slips before the bell after a 49% surge — what traders watch next for MGRX

Mangoceuticals shares fell about 4% to 51 cents in premarket trading Monday, easing after a 49% surge Friday that followed news of strong early sales for its $99-a-month testosterone therapy. Trading volume Friday spiked to 349 million shares. The company remains below Nasdaq’s $1 minimum bid requirement and has until August 3, 2026, to regain compliance.
23 February 2026
·
Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals announced partnerships with Eli Lilly and Novo Nordisk to offer official access to Zepbound and Wegovy through new telehealth programs, MangoRx Direct and PeachesRx Direct. Membership costs $99 per month, with GLP‑1 drugs starting at $499 monthly, no insurance required. MGRX shares jumped over 25% pre-market before retreating. The company recently settled a lawsuit with Lilly and reported a $10.3 million net loss.
13 November 2025
····

Stock Market Today

  • Neo Performance Materials Stock Dips Amid Valuation Debate Following Volatile Trading
    March 20, 2026, 1:59 PM EDT. Neo Performance Materials (TSX:NEO) experienced a steep 14.1% drop in share price in one day and 22.5% over the past week, despite a strong 90-day gain of 27.46% and a 1-year return exceeding 118%. The Toronto-based company, active in rare earth materials across multiple regions, sees divided views on valuation. A popular market narrative values shares at CA$25.33, suggesting a nearly 20% undervaluation against Friday's CA$20.47 close. However, a discounted cash flow (DCF) analysis counters this with a much lower fair value of CA$13.16, indicating the stock could be overvalued. The stock's future hinges on execution at a new Estonian sintered magnet plant and demand from Europe's automotive sector. Investors face a clear dilemma amid this volatility and contrasting valuation models.
Go toTop